Growth-differentiation factor-15 and tissue doppler ımaging in detection of asymptomatic anthracycline cardiomyopathy in childhood cancer survivors

Growth-differentiation Factor-15 and Tissue Doppler Imaging in Detection of Anthracycline-induced Cardiomyopathy During Therapy of Childhood Cancers

“…Chemotherapy-induced cardiotoxicity may develop in patients who had childhood cancers, independent of clinical risk factors. 7 In our study, there were no statistically significant differences in the serum levels of GDF-15 after the pretreatment with 200 mg/m 2 of anthracyclines, but the levels were increased after the treatment compared with those before the treatment. A significant increase in serum GDF-15 levels was determined at 200 mg/m 2 of anthracycline intake in our study (P = 0.01).…”

“…[8][9][10][11][12] In our previous study, the mean plasma GDF-15 levels of patients who had completed chemotherapy treatment with anthracyclines were significantly higher than those of healthy controls. 7 The aim of this study was to evaluate the importance of GDF-15 and TDI in the early detection of anthracycline-induced cardiomyopathy during the treatment of childhood cancers.…”

“…However, recent studies on the use of imaging modalities, especially tissue Doppler imaging (TDI), in detecting anthracycline-related cardiotoxicity have reported positive findings. [2][3][4][5][6][7] The utility of a number of different biomarkers, such as cardiac troponin T, N-terminal probrain natriuretic peptide, and high sensitivity C-reactive protein, as diagnostic markers of anthracycline-related cardiotoxicity has been studied. 1 Growth-differentiation factor-15 (GDF-15) is a member of the transforming growth factor b-cytokine superfamily.…”

Successful recovery and allogeneic stem cell transplant following chemotherapy-induced severe cardiomyopathy: literature review of management and prognostic factors

“…Other AIC biomarkers, including growth differentiating factors-15 (GDF-15), CBR1, AKR1A1 and AKR7A2 protein, and topoisomerase2β (Top2β) were studied in different populations and can also be used 15 16. In childhood cancer survivors GDF-15, a member of TGF superfamily, can be used as a marker of AIC 17. Metabolism of anthracyclines is mediated predominantly by enzymes like carbonyl reductases (CBR) and aldo-keto reductases (AKR1A1, AKR7A2).…”

Relevance of Tricuspid Annular Peak Systolic Velocity (S′) to Detect Systolic Right-Ventricular Impairment After Anthracycline Cancer Treatment in Childhood

“…In our opinion, this is an excellent article describing the effect of cumulative dose on left-ventricular (LV) and right-ventricular (RV) function in pediatric patients receiving cancer treatment using tissue Doppler imaging (TDI) parameters. The importance of TDI measurements of LV and RV function in the process of dose evaluation of anthracycline treatment has also been described to be a clinically useful technique for the assessment of LV and RV function [1]. Kocabas et al [2] clearly state that abnormalities of RV and the LV function were observed even with a cumulative anthracycline dose \120 mg/m 2 .…”